Your browser is no longer supported. Please, upgrade your browser.
Settings
PRFX PainReform Ltd. daily Stock Chart
PRFX [NASD]
PainReform Ltd.
Index- P/E- EPS (ttm)-0.27 Insider Own- Shs Outstand9.20M Perf Week-9.51%
Market Cap50.78M Forward P/E- EPS next Y- Insider Trans- Shs Float3.23M Perf Month-
Income-2.40M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y-28.60% Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.10 P/C56.43 EPS next 5Y- ROE- 52W Range5.25 - 7.85 Perf YTD-18.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.68% Beta-
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low5.14% ATR0.58
Employees3 Current Ratio0.20 Sales Q/Q- Oper. Margin- RSI (14)- Volatility9.01% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.19 Prev Close5.70
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume114.06K Price5.52
Recom- SMA20-12.02% SMA50-12.02% SMA200-12.02% Volume22,022 Change-3.16%
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.